BUZZ-U.S. STOCKS ON THE MOVE-Aeropostale, Ford, Bind Therapeutics

(Adds Ford, Alcatel (Paris: FR0000130007 - news) -Lucent, Acura, Aveo, Banco Santander (Amsterdam: SANT.AS - news) , CytRx) (For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

U.S. stocks climbed on Thursday, after equities snapped a five-day losing skid and data pointed to a labor market that continued to strengthen. The Dow Jones industrial average was up 1.35 percent at 17,821.49, the S&P 500 was up 1.28 percent at 2,051.92 and the Nasdaq Composite was up 1.01 percent at 4,697.29.

** FORD MOTOR CO (NYSE: F - news) , $15.415, +2.49 pct

The carmaker raised its quarterly dividend 20 percent; to pay 15 cents per share first-quarter dividend. Ford on Monday reported 1 percent rise in December sales.

** ACURA PHARMACEUTICALS INC (NasdaqCM: ACUR - news) , $0.6499, +14.42 pct

Egalet Corp to market the drugmaker's painkiller Oxecta. Under deal, Acura will receive $5 million upfront and additional $2.5 million on first sale of tablet in United States.

The company will also receive additional $12.5 million when annual sales of tablet reach $150 million.

** BANCO SANTANDER SA, $7.67, -2.91 pct

Santander suspended as bank says to sell shares to hike capital by EUR 7.5 billion and cuts its dividend.

Other Spanish banks hit: BBVA down 0.8 percent, Caixabank down 1.6 percent and Banco Popular trims gains to be up 0.2percent -- all among the worst performers (apart from Greek banks) and lagging the 1.3 percent rise in Euro STOXX banks.

Euro STOXX banks had been up as much as 3 percent before the first reports of a capital boost.

** ALCATEL LUCENT SA, $3.45, +2.37 pct

Credit Suisse (NYSE: CS - news) upgraded the French telecom company's stock to "outperform" from "neutral" and raised its price target 3.75 euros from 3.25.

** CYTRX CORP, $3.72, +9.73 pct

CytRx said its cancer drug was effective against a type of skin cancer in HIV+ patients. Interim data from an ongoing mid-stage study showed that the drug, aldoxorubicin, stopped tumor growth in HIV+ patients suffering from Kaposi's Sarcoma, the company said on Thursday.

** AVEO ONCOLOGY, $0.9015, +7.96 pct

The drug developer said European regulators confirmed it is eligible to submit an application to market its lead drug, tivozanib, to treat a form of kidney cancer.

The news comes a day after the company outlined plans to cut two-thirds of its workforce. Aveo has suffered many setbacks and chopped its workforce as tivozanib had failed in multiple cancer indications.

** BIND THERAPEUTICS INC (NasdaqGS: BIND - news) , $8.54, +65.83 pct

The drug developer said it enrolled its first patient in a mid-stage trial on lung cancer drug BIND-014. The Trial will focus on lung cancer patients with KRAS mutant, who have historically been unresponsive to standard treatment. Bind also attained milestone as part of agreement with Pfizer Inc (NYSE: PFE - news)

** AMERICAN EAGLE OUTFITTERS INC (NYSE: AEO - news) , $14.435, -1.33 pct

** AEROPOSTALE INC, $2.69, +19.03 pct

The teen apparel retailers raised their estimates for the holiday shopping quarter as margins improved due to fewer discounts.

** GW PHARMACEUTICALS PLC (NasdaqGM: GWPH - news) , $71.875, +1.15 pct

An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study. GW Pharmaceuticals , which is developing the drug Sativex for pain in collaboration with Japan's Otsuka Corp, said the first of three late-stage trials found no statistically significant difference between subjects using its product and those given a placebo.

** CONSTELLATION BRANDS INC (NYSE: STZ - news) , $107.98, +4.78 pct

The alcoholic beverage maker raised its full-year earnings forecast after reporting higher-than-expected quarterly sales and profit, helped by increased sales of its beer brands such as Corona and Modelo.

** ABBVIE INC (Xetra: 4AB.DE - news) , $67.99, +1.58 pct

** NEUROCRINE BIOSCIENCES INC (NasdaqGS: NBIX - news) , $27.025, +23.51 pct

An experimental drug being developed by AbbVie and Neurocrine successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.

** APOLLO EDUCATION GROUP, $27.59, -13.40 pct

** ITT Educational Services Inc (NYSE: ESI - news) , $9.27, +0.65 pct

The for-profit education provider's quarterly profit plunged nearly 66 percent as student enrollments fell. New (KOSDAQ: 160550.KQ - news) degreed enrollments at Apollo's flagship University of Phoenix (LSE: PHNX.L - news) fell 5 percent to 39,600 in the first quarter.

** INFINITY PHARMA, $14.81, -9.31 pct

The company said it would stop testing its lead drug as a treatment for rheumatoid arthritis after it failed the main goal in a mid-stage study. Duvelisib - being developed with AbbVie Inc in oncology - will still be tested to treat various types of blood cancer.

** IMPAX LABORATORIES INC (NasdaqGS: IPXL - news) , $34.9, +12.62 pct

The company said the U.S. Food and Drug Administration had approved Rytary, its drug for treating Parkinson's disease, which was previously rejected due to issues with the company's manufacturing plant in Hayward, California. The agency had also raised concerns about Impax's factory in Taiwan.

** MANNKIND CORP (NasdaqGM: MNKD - news) , $5.7899, +2.48 pct

The drugmaker said it earned $50 million in milestone payments from Sanofi SA related to its licensing deal with the French drugmaker.

** NOVARTIS AG (Xetra: 904278 - news) , $94.45, +2.59 pct

The Swiss pharma group said it will submit regulatory applications in the United States for two treatments against chronic obstructive pulmonary disease after late-stage clinical studies yielded good results.

** SANCHEZ ENERGY CORP, $8.477, +6.36 pct

The oil producer operating in Texas and Mississippi, cut its 2015 capital budget on Wednesday by 60 percent, citing a recent drop in crude oil prices.

** HALOZYME THERAPEUTICS INC (NasdaqGS: HALO - news) , $13.98, +11.66 pct

The drugmaker believes it has a multibillion-dollar cancer drug on its hands. The drug, PEGPH20, being tested against pancreatic cancer, has the potential to help treat several other types of solid tumor cancers, its chief executive said in an interview.

** INSULET CORP, $39.93, -10.33 pct

The medical device maker slashed its fourth-quarter revenue estimate, citing delays in shipments of its non-insulin drug delivery products from the fourth quarter of 2014 to the first quarter of 2015.

The company now expects fourth-quarter revenue of $71 million-$73 million, down from its previous forecast of $76 million-$81 million.

** BIODEL INC (NasdaqCM: BIOD - news) , $1.83, +26.21 pct

The drug developer's preliminary mid-stage trial results showed that its experimental insulin drug may be more effective than Eli Lilly and Co therapies in controlling glucose in patients when dosed immediately before breakfast.

** NEPHROGENEX INC (NasdaqCM: NRX - news) , $10.11, +9.77 pct

The kidney disease drug developer said European Medicines Agency indicated current late-stage study of its drug to treat diabetic nephropathy could be adequate to support a marketing application.

** RESOURCES CONNECTION INC (NasdaqGS: RECN - news) , $16.89, +1.93 pct

The consulting firm reported a better-than-expected profit for the second quarter ending Nov. 29, as it earned more money from services such as accounting and corporate advisory. The company's revenue also beat average analyst estimate.

** AMTRUST FINANCIAL SERVICES INC (NasdaqGS: AFSI - news) , $51.0801, -5.41 pct

The property and casualty insurer said it will sell 3 million common shares in a public offering. Up to Wednesday's close, the stock had risen 55.5 pct over the last year.

** ULTRAGENYX PHARMACEUTICAL INC (NasdaqGS: RARE - news) , $51.2931, +5.43 pct

Canaccord Genuity (Other OTC: CCORF - news) started coverage of the company's stock with a "buy" rating and a $60 target price. (Compiled by Lehar Maan; Editing by Joyjeet Das)